Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro platelet activation by an echo contrast agent.

Kouichirou Shigeta1, Nobuyuki Taniguchi, Kiyoka Omoto

  • 1Department of Clinical Laboratory Medicine, Jichi Medical School, Tochigi-ken, Japan.

Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine
|April 16, 2003
PubMed
Summary

A galactose-based echo contrast agent, Levovist, did not activate platelets in vitro at routine concentrations. Ultrasound exposure showed minimal effect, even at high Levovist concentrations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of the collecting lymphatic vessel responsible for dermal backflow using indocyanine green lymphography-guided contrast-enhanced ultrasound.

Journal of vascular surgery. Venous and lymphatic disorders·2026
Same author

C-C motif chemokine 3 interferes with oligodendrocyte maturation in the brain.

Biochemical and biophysical research communications·2026
Same author

Prevalence of Significant Coronary Artery Stenosis and Relationship with Carotid Maximum Intima-Media Thickness in Asymptomatic Patients with Moderate-to-Severe Chronic Kidney Disease: A Single-Center, Prospective, Cross-Sectional Study.

Vascular health and risk management·2025
Same author

Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent/resistant cGVHD: clinical outcomes from a Japanese study.

Bone marrow transplantation·2025
Same author

Routine Laboratory Tests Predict 72-h Fatality in Patients With D-Dimer Levels ≥ 2 μg/mL: A Retrospective Cohort Study Comparing Statistical and Machine Learning Models.

Journal of clinical laboratory analysis·2025
Same author

Predicting 72-Hour Fatality in Severe Hyperphosphatemia: A Comparative Analysis of Multivariate Logistic Regression and Machine Learning Models in a Single-Center Study.

Cureus·2025

Area of Science:

  • Biomedical Engineering
  • Hematology
  • Diagnostic Imaging

Background:

  • Platelet activation is a critical factor in hemostasis and thrombosis.
  • Microbubble-based ultrasound contrast agents are widely used in medical imaging.
  • Understanding potential interactions between contrast agents and blood components is crucial for patient safety.

Purpose of the Study:

  • To investigate the in vitro platelet-activating potential of Levovist, an ultrasound echo contrast agent.
  • To determine if Levovist or its component, galactose, activates platelets under simulated clinical conditions.

Main Methods:

  • Whole blood samples from healthy volunteers were incubated with varying concentrations of Levovist and galactose.
  • Samples were exposed to ultrasound (3.5 MHz, mechanical index 1.9) for 5 minutes.

Related Experiment Videos

  • Platelet activation was assessed using flow cytometry by measuring CD61 and CD62P (P-selectin) expression.

    • Main Results:

    • Platelet activation markers (CD62P) increased with higher concentrations of Levovist and galactose.
    • The effects of Levovist and galactose on platelet activation were comparable.
    • Ultrasound exposure did not significantly enhance platelet activation, except at the highest Levovist concentration (75 mg/mL).

    Conclusions:

    • Levovist, a galactose-based ultrasound contrast agent, does not activate platelets at concentrations typically used in clinical practice.
    • The study suggests a low risk of in vitro platelet activation with routine use of this contrast agent.
    • Further in vivo studies may be warranted to confirm these findings.